A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

Heart failure plagues industrialized nations, killing more people than any other disease. It
usually results from a deficiency of specialized cardiac muscle cells known as …

Rationale: Embryonic stem cells (ESCs) hold great promise for cardiac regeneration but are
susceptible to various concerns. Recently, salutary effects of stem cells have been …

Human induced pluripotent stem cells (hiPSCs) hold promise for myocardial repair following
injury, but preclinical studies in large animal models are required to determine optimal cell …

Background c-kit-positive, lineage-negative cardiac stem cells (CSCs) improve post-
infarction left ventricular (LV) dysfunction when administered to animals. We undertook a …

Cardiovascular disease is the leading cause of death worldwide. Although investment in
drug discovery and development has been sky-rocketing, the number of approved drugs has …

Despite significant therapeutic advances, the prognosis of patients with heart failure (HF)
remains poor, and current therapeutic approaches are palliative in the sense that they do not …

Poor functional survival of the engrafted stem cells limits the therapeutic efficacy of stem-cell-
based therapy for myocardial infarction (MI). Cardiac patch-based system for cardiac repair …

In the past decade, substantial evidence supports the paradigm that stem cells exert their
reparative and regenerative effects, in large part, through the release of biologically active …

Background—SCIPIO is a first-in-human, phase 1, randomized, open-label trial of
autologous c-kit+ cardiac stem cells (CSCs) in patients with heart failure of ischemic etiology …